{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T00:02:55Z","timestamp":1759104175535,"version":"3.44.0"},"reference-count":27,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Immunology Letters"],"published-print":{"date-parts":[[2022,4]]},"DOI":"10.1016\/j.imlet.2022.03.002","type":"journal-article","created":{"date-parts":[[2022,3,10]],"date-time":"2022-03-10T20:22:15Z","timestamp":1646943735000},"page":"40-42","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Overlapping GAD65-associated autoimmune neurological syndromes and type 1 diabetes"],"prefix":"10.1016","volume":"244","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3930-8056","authenticated-orcid":false,"given":"Fatme Seval","family":"Ismail","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.imlet.2022.03.002_bib0001","doi-asserted-by":"crossref","first-page":"2449","DOI":"10.1016\/S0140-6736(18)31320-5","article-title":"Type 1 diabetes","volume":"391","author":"DiMeglio","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.imlet.2022.03.002_bib0002","doi-asserted-by":"crossref","first-page":"1690","DOI":"10.2337\/db15-1058","article-title":"Identification of tetraspanin-7 as target of autoantibodies in type 1 diabetes","volume":"65","author":"McLaughlin","year":"2016","journal-title":"Diabetes"},{"key":"10.1016\/j.imlet.2022.03.002_bib0003","doi-asserted-by":"crossref","first-page":"1394","DOI":"10.1172\/JCI116714","article-title":"Prevalence of autoantibodies to the 65- and 67-kD isoforms of glutamate decarboxylase in insulin-dependent diabetes mellitus","volume":"92","author":"Seissler","year":"1993","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.imlet.2022.03.002_bib0004","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1172\/JCI125178","article-title":"Autoimmune seizures and epilepsy","volume":"129","author":"Geis","year":"2019","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.imlet.2022.03.002_bib0005","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1001\/archneur.58.2.225","article-title":"Cerebellar ataxia with anti-glutamic acid decarboxylase antibodies: study of 14 patients","volume":"58","author":"Honnorat","year":"2001","journal-title":"Arch. Neurol."},{"key":"10.1016\/j.imlet.2022.03.002_bib0006","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1002\/ana.21917","article-title":"Antibodies to glutamic acid decarboxylase define a form of limbic encephalitis","volume":"67","author":"Malter","year":"2010","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.imlet.2022.03.002_bib0007","doi-asserted-by":"crossref","first-page":"1603","DOI":"10.1007\/s00415-008-0986-4","article-title":"New-onset focal epilepsy with palatal tremor and glutamic acid decarboxylase antibodies responding to intravenous immunoglobulin","volume":"255","author":"Marnane","year":"2008","journal-title":"J. Neurol."},{"key":"10.1016\/j.imlet.2022.03.002_bib0008","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1056\/NEJM198804213181602","article-title":"Autoantibodies to glutamic acid decarboxylase in a patient with stiff-man syndrome, epilepsy, and type I diabetes mellitus","volume":"318","author":"Solimena","year":"1988","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.imlet.2022.03.002_bib0009","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.4065\/81.9.1207","article-title":"Glutamic acid decarboxylase autoimmunity with brainstem, extrapyramidal, and spinal cord dysfunction","volume":"81","author":"Pittock","year":"2006","journal-title":"Mayo Clin. Proc."},{"key":"10.1016\/j.imlet.2022.03.002_bib0010","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1136\/jnnp-2020-325275","article-title":"Clinical spectrum of high-titre GAD65 antibodies","volume":"92","author":"Budhram","year":"2021","journal-title":"J. Neurol. Neurosurg. Psychiatr."},{"key":"10.1016\/j.imlet.2022.03.002_bib0011","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1212\/WNL.57.5.780","article-title":"Stiff person syndrome: quantification, specificity, and intrathecal synthesis of GAD65 antibodies","volume":"57","author":"Dalakas","year":"2001","journal-title":"Neurology"},{"key":"10.1016\/j.imlet.2022.03.002_bib0012","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/j.yebeh.2018.01.021","article-title":"Antiglutamic acid decarboxylase 65 (GAD65) antibody-associated epilepsy","volume":"80","author":"Daif","year":"2018","journal-title":"Epilepsy Behav."},{"key":"10.1016\/j.imlet.2022.03.002_bib0013","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1007\/s004150050443","article-title":"Plasmapheresis and immunosuppression in stiff-man syndrome with type 1 diabetes: a 2-year study","volume":"246","author":"Hao","year":"1999","journal-title":"J. Neurol."},{"key":"10.1016\/j.imlet.2022.03.002_bib0014","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1016\/j.transci.2019.03.015","article-title":"Role of plasma exchange in stiff person syndrome","volume":"58","author":"Albahra","year":"2019","journal-title":"Transfus. Apher. Sci"},{"key":"10.1016\/j.imlet.2022.03.002_bib0015","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/0022-510X(91)90198-G","article-title":"Effect of intraventricular injection of an anti-Purkinje cell antibody (anti-Yo) in a guinea pig model","volume":"106","author":"Graus","year":"1991","journal-title":"J. Neurol. Sci."},{"key":"10.1016\/j.imlet.2022.03.002_bib0016","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1007\/BF00687805","article-title":"Immunofluorescent labeling of nonhuman cerebellar tissue with sera from patients with systemic cancer and paraneoplastic cerebellar degeneration","volume":"67","author":"Greenlee","year":"1985","journal-title":"Acta Neuropathol."},{"key":"10.1016\/j.imlet.2022.03.002_bib0017","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1186\/1742-2094-6-31","article-title":"Cerebellar Purkinje cells incorporate immunoglobulins and immunotoxins in vitro: implications for human neurological disease and immunotherapeutics","volume":"6","author":"Hill","year":"2009","journal-title":"J. Neuroinflammation"},{"key":"10.1016\/j.imlet.2022.03.002_bib0018","doi-asserted-by":"crossref","first-page":"78","DOI":"10.3389\/fnbeh.2015.00078","article-title":"Disease-specific monoclonal antibodies targeting glutamate decarboxylase impair GABAergic neurotransmission and affect motor learning and behavioral functions","volume":"9","author":"Manto","year":"2015","journal-title":"Front. Behav. Neurosci"},{"key":"10.1016\/j.imlet.2022.03.002_bib0019","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1097\/NEN.0b013e3181f0c82b","article-title":"Purkinje cell death after uptake of anti-Yo antibodies in cerebellar slice cultures","volume":"69","author":"Greenlee","year":"2010","journal-title":"J. Neuropathol. Exp. Neurol."},{"key":"10.1016\/j.imlet.2022.03.002_bib0020","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1002\/ana.410440209","article-title":"Inhibition of gamma-aminobutyric acid synthesis by glutamic acid decarboxylase autoantibodies in stiff-man syndrome","volume":"44","author":"Dinkel","year":"1998","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.imlet.2022.03.002_bib0021","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/1750-1172-6-3","article-title":"Respective implications of glutamate decarboxylase antibodies in stiff person syndrome and cerebellar ataxia","volume":"6","author":"Manto","year":"2011","journal-title":"Orphanet. J. Rare. Dis."},{"key":"10.1016\/j.imlet.2022.03.002_bib0022","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1002\/mus.25565","article-title":"GAD65 neurological autoimmunity","volume":"56","author":"McKeon","year":"2017","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.imlet.2022.03.002_bib0023","doi-asserted-by":"crossref","first-page":"3701","DOI":"10.3390\/ijms21103701","article-title":"Neurological syndromes associated with anti-GAD antibodies","volume":"21","author":"Dade","year":"2020","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.imlet.2022.03.002_bib0024","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1111\/1753-0407.12627","article-title":"Latent autoimmune diabetes and limbic encephalitis with antibodies against glutamic acid decarboxylase","volume":"10","author":"Popkirov","year":"2018","journal-title":"J. Diabetes"},{"key":"10.1016\/j.imlet.2022.03.002_bib0025","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1126\/science.abh1657","article-title":"Strategies for durable \u03b2 cell replacement in type 1 diabetes","volume":"373","author":"Brusko","year":"2021","journal-title":"Science"},{"key":"10.1016\/j.imlet.2022.03.002_bib0026","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1126\/science.abi4742","article-title":"Preventing type 1 diabetes in childhood","volume":"373","author":"Dayan","year":"2021","journal-title":"Science"},{"key":"10.1016\/j.imlet.2022.03.002_bib0027","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1126\/science.abh1654","article-title":"Immunotherapy: building a bridge to a cure for type 1 diabetes","volume":"373","author":"Bluestone","year":"2021","journal-title":"Science"}],"container-title":["Immunology Letters"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165247822000359?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165247822000359?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,28]],"date-time":"2025-09-28T07:40:33Z","timestamp":1759045233000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0165247822000359"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4]]},"references-count":27,"alternative-id":["S0165247822000359"],"URL":"https:\/\/doi.org\/10.1016\/j.imlet.2022.03.002","relation":{},"ISSN":["0165-2478"],"issn-type":[{"type":"print","value":"0165-2478"}],"subject":[],"published":{"date-parts":[[2022,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Overlapping GAD65-associated autoimmune neurological syndromes and type 1 diabetes","name":"articletitle","label":"Article Title"},{"value":"Immunology Letters","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.imlet.2022.03.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 European Federation of Immunological Societies. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}